Eloxx Pharmaceuticals (ELOX) Reports Q1 Loss of $0.31/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Eloxx Pharmaceuticals Reports First Quarter 2018 Financial and Operating Results and Provides Business Update
May 10, 2018 4:01 PM EDTCompany on track to initiate Phase 2 clinical trials for investigational drug ELX-02 in cystic fibrosis and cystinosis in 2018 and sufficiently funded to top line dataÂ
Formation of Scientific Advisory Board with expertise in nonsense mutations and nonsense mediated decay
Company to host webcast and conference call on Thursday, May 10, 2018 at 4:30 pm ET
WALTHAM, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Eloxx), (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis,... More
